Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

BACKGROUND: Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-...

Full description

Bibliographic Details
Main Authors: Wojtkowiak, Jonathan W., Cornnell, Heather C., Matsumoto, Shingo, Saito, Keita, Takakusagi, Yoichi, Dutta, Prasanta, Kim, Munju, Zhang, Xiaomeng, Leos, Rafael, Bailey, Kate M., Martinez, Gary, Lloyd, Mark C., Weber, Craig, Mitchell, James B., Lynch, Ronald M., Baker, Amanda F., Gatenby, Robert A., Rejniak, Katarzyna A., Hart, Charles, Krishna, Murali C., Gillies, Robert J.
Other Authors: Department of Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute
Language:en
Published: BioMed Central 2016
Subjects:
Hypoxia
Hypoxia-activated prodrugs
TH-302
Tumor microenvironment
Metabolism
Pancreatic cancer
Functional imaging
Computational modeling
Online Access:http://hdl.handle.net/10150/610264
http://arizona.openrepository.com/arizona/handle/10150/610264

Internet

http://hdl.handle.net/10150/610264
http://arizona.openrepository.com/arizona/handle/10150/610264

Similar Items